US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3101

+0.00993.30%

Post-market: 0.32000.0099+3.19%19:28 EDT

Volume:58.50K

Turnover:18.49K

Market Cap:6.30M

PE:4.06

High:0.3499

Open:0.3103

Low:0.3002

Close:0.3002

Loading ...

Overview Company News Filings

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Why Tempus AI (TEM) Went Up On Friday?

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Press Release: Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

Exciting Crypto ETF Expansion: HashDex Adds Litecoin, XRP & More to Nasdaq Fund

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

ORYZON to Provide Corporate Progress Updates at Several Events in March-April

Tempus Announces Acquisition of Deep 6 AI

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

Nine's Domain tax bill could reach $240 million if CoStar agrees deal

Shell plc Fourth Quarter 2024 Euro and GBP Equivalent Dividend Payments

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Shell plc announces changes to the Executive Committee

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.3101,"timestamp":1746216000000,"preClose":0.3002,"halted":0,"volume":58497,"hourTrading":{"tag":"盘后","latestPrice":0.32,"preClose":0.3101,"latestTime":"19:28 EDT","volume":9523,"amount":3178.6987,"timestamp":1746228503700},"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Market Closed","change":0.0099,"latestTime":"05-02 16:00:00 EDT","open":0.3103,"high":0.3499,"low":0.3002,"amount":18490.4863713,"amplitude":0.165556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.076408,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.3002,"dividendRate":0.644953,"preHourTrading":{"tag":"盘前","latestPrice":0.297,"preClose":0.3301,"latestTime":"09:27 EDT","volume":1100,"amount":329.34,"timestamp":1746192470100},"postHourTrading":{"tag":"盘后","latestPrice":0.32,"preClose":0.3101,"latestTime":"19:28 EDT","volume":9523,"amount":3178.6987,"timestamp":1746228503700},"volumeRatio":1.0030590569690505},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":1.0030590569690505,"shares":20320000,"dividePrice":0.2,"high":0.3499,"amplitude":0.165556,"preClose":0.3002,"low":0.3002,"week52Low":0.28,"pbRate":"0.98","psRate":"0.28","week52High":1.8,"institutionHeld":0.7857,"latestPrice":0.3101,"eps":0.076408,"divideRate":0.644953,"volume":58497,"delay":0,"ttmEps":0.076408,"open":0.3103,"prevYearClose":0.66,"prevWeekClose":0.37,"prevMonthClose":0.3446,"prevQuarterClose":0.48,"fiveDayClose":0.37,"twentyDayClose":0.448,"sixtyDayClose":0.5561},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522880537","title":"Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880537","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880537?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:45","pubTimestamp":1742993100,"startTime":"0","endTime":"0","summary":"- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market. - Presentation follows Investor KOL Event and Company Update on March 25th. NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay here.Generate clinical data in first non-malignant indication from sickle cell disease allogeneic stem cell transplant trial at Columbia University","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","HMA","ATNM","NCI","BK4139","BK4202","CR"],"gpt_icon":0},{"id":"2522022501","title":"Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022501","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022501?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:00","pubTimestamp":1742896800,"startTime":"0","endTime":"0","summary":"- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential. - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined. - Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs. Actinium's company update will highlight the 3 separate potential multi-billion-dollar blockbuster market opportunities being pursued with its targeted radiotherapies including the following:. - Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4590","BK4181","BK4218","BK4161","KOL","HMA","NCI","BK4585","HST","ATNM","BK4144","BK4561","ET","CR","BK4139","BK4202","BK4581"],"gpt_icon":0},{"id":"2522707005","title":"Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707005","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707005?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:15","pubTimestamp":1742847300,"startTime":"0","endTime":"0","summary":"NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies,today announced it has entered into an agreement for the supply of Actinium-225  with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia  and other myeloid indications.E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","HMA","ATNM","NCI","BK4139","BK4202","CR"],"gpt_icon":0},{"id":"2521976342","title":"Why Tempus AI (TEM) Went Up On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521976342","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521976342?lang=en_us&edition=fundamental","pubTime":"2025-03-22 15:15","pubTimestamp":1742627713,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Stocks Lead Friday’s Charge. In this article, we are going to take a look at where Tempus AI  stands against other stocks that lead Friday’s charge.The stock market finished in the green territory on Friday, albeit muted trading persisted over the lack of catalysts to fuel investing appetite.The tech-heavy Nasdaq led gains among Wall Street’s benchmark indices, finishing up by 0.52 percent. Meanwhile, both the Dow Jones and S&P 500 ended the week eking out 0.08-percent gains.Ten companies mirrored the broader market optimism, finishing the week with modest gains. In this article, we have identified today’s top performers and detailed the reasons behind their gains.To come up with the list, we considered only the stocks with $2 billion in market capitalization and $5 million in trading volume.Cathie Wood, co-founder and CEO of Ark Invest, for instance, included TEM in her portfolio of AI stocks.Earlier this month, TEM announced the acquisition of Deep ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-tem-went-071513790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4202","BK4613","IE00BVYPNW00.USD","EMR","SQQQ","SG9999011175.SGD","QLD","USAW.SI","TEM","TSYW.SI","USJW.SI","NQmain","LU2355687059.USD","IE00BGHQF631.EUR","IE00B3PB1722.GBP","BK4533","TQQQ","LU1861559042.SGD","BK4597","BK4588","QID","NVIW.SI","BK4611",".IXIC","LU1861558580.USD","SG9999003800.SGD","BK4096","BK4585","NCI","IE00BVYPNV92.GBP","IE00BDGV0183.EUR","IE00B42XCP33.USD","BK4121","PSQ","BK4543"],"gpt_icon":1},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4585","LU1571399168.USD","LU2355687059.USD","BK4232","BK4588","BK4109","LU0985320562.USD","BK4022","BK4139","BK4183","BK4161","PR","BK4213","ORR","ASH","LU2463526074.USD","BK4218","ODD","BK4107","CR","LU1699723380.USD","BK4202","SLS","BK4181","R","ALL","NCI","INN","OS","BK4097"],"gpt_icon":0},{"id":"2520591458","title":"Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2520591458","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520591458?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"REYOBIQ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM)  HOUSTON, March  20, 2025  (GLOBE NEWSWIRE) -- Plus ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","NCI","LENZ","CNS","BK4135"],"gpt_icon":0},{"id":"2520927182","title":"Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520927182","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520927182?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"-  Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. -  Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA and OPDIVO in solid tumor indications. - Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology's hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025. - Iomab-ACT commercial CAR-T trial to initiate patient enrollment with clinical proof of concept data expected in 2H:2025; Iomab-ACT sickle cell disease trial expected to initiate in 1H:2025. Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes  across multiple treatment settings. Sandesh Seth, Actinium's Chairman and CEO, said, \"We have made significant progress across our pipeline ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOL","BK4588","BK4585","BK4218","HMA","BK4202","ACT","ATNM","BK4181","HST","NCI","BK4161","CR","BK4139"],"gpt_icon":0},{"id":"2520033549","title":"Press Release: Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520033549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520033549?lang=en_us&edition=fundamental","pubTime":"2025-03-19 18:30","pubTimestamp":1742380200,"startTime":"0","endTime":"0","summary":"-- Targeting final FDA approval of YUTREPIA after expiration of. -- Advancing pipeline of inhaled treprostinil products in clinical studies. -- Strengthened financial position by up to $100 million via amendment to. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: \"Building on our progress this past year, Liquidia has strengthened its financial position, with up to an additional $100 million available pursuant to an amendment to its existing financing agreement with HCRx, while remaining poised for the potential approval and commercialization of YUTREPIA after the expiration on May 23, 2025 of the regulatory exclusivity that is currently preventing final approval. We continue to have our sights set on fulfilling our promise to provide physicians and patients with what we believe can be a much-needed therapeutic alternative, and potentially the prostacyclin of first choice, for patients with PAH and PH-ILD.\". Liquidia continues to progress clinical studies of L606  inhalation ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4099","TM","BK4022","BK4604","BK4232","BK4202","BK4588","NCI","R","BK4007","LQDA","BK4555","BK4585"],"gpt_icon":0},{"id":"2520784126","title":"Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®","url":"https://stock-news.laohu8.com/highlight/detail?id=2520784126","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520784126?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA or OPDIVO can result in improved patient outcomes. - MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA and OPDIVO. - Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33. - Clinical proof of concept data expected in 2025 could potentially open up a multi-billion-dollar market opportunity for Actimab-A as a combination therapy with PD-1 inhibitors in multiple solid tumors. Actimab-A is Actinium's lead radiotherapeutic that delivers Actinium-225, a potent alpha-emitter radioisotope payload that can produce lethal double strand DNA br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","LU1929549753.HKD","BK4023","SG9999015358.SGD","PD","LU0320765646.SGD","LU2023250504.SGD","BK4202","LU0965509283.SGD","LU1057294990.SGD","SG9999014542.SGD","LU1699723380.USD","LU2324357040.USD","SG9999002232.USD","SG9999013999.USD","IE00B2B36J28.USD","LU1989772840.SGD","MRK","LU1037948541.HKD","LU1116320901.HKD","SG9999002224.SGD","IE0002141913.USD","LU1116320737.USD","LU1037948897.HKD","IE00BFTCPJ56.SGD","LU0985320562.USD","SG9999015341.SGD","LU1989772923.USD","LU1983299246.USD","ATNM","IE00BJT1NW94.SGD","LU1974910355.USD","HMA","LU1093756325.SGD","LU1989771016.USD","LU1941712348.USD","LU0965509101.SGD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU1169589451.USD","LU2023250843.SGD","LU1941712264.USD","SG9999001176.SGD","LU1934455277.USD","SGXZ57979304.SGD","IE00B4R5TH58.HKD","CR","LU1934455194.USD","LU0266013472.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2520684400","title":"Exciting Crypto ETF Expansion: HashDex Adds Litecoin, XRP & More to Nasdaq Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2520684400","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520684400?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:44","pubTimestamp":1742247863,"startTime":"0","endTime":"0","summary":"Get ready for a significant shake-up in the crypto investment landscape!HashDex, a well-known cryptocurrency asset management firm, is making waves with its latest move. They’re not just sitting still; they’re actively expanding their offerings to give investors broader access to the exciting world of digital assets. The buzz is all about their Nasdaq Crypto Index ETF , which is set to welcome a host of new cryptocurrencies into its fold. This update could be a game-changer for anyone looking to diversify their crypto portfolio through a traditional investment vehicle.Understanding the HashDex ETF and its Crypto ETF Expansion. This is a diverse selection, covering different sectors within the cryptocurrency market, from payments and smart contracts","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d897b851a79047c48a2366/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4157","BK4585","IE00B64PRP62.GBP","UNI.USD.CC","SQQQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","QID","TON.USD.HKCC","LTC.USD.HKCC","BK4588","NVIW.SI","NQmain","BK4203","BK4112","TON.USD.CC","USAW.SI","LINK","QLD",".IXIC","NDAQ","SOL.USD.HKCC","TSYW.SI","LU2210150020.SGD","LU2095319765.USD","SOL","BK4550","LTC","NCIQ","UNI.USD.HKCC","MNQmain","BK4202","LU2210149790.SGD","USJW.SI","BK4519","AVAX.USD.HKCC","APT.USD.HKCC","APT.USD.CC","BK4129","IE00BGHQF748.EUR","NCI","PSQ","TQQQ","BK4225","AVAX.USD.CC","FDN","LTC.USD.CC"],"gpt_icon":1},{"id":"2520443526","title":"Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443526","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443526?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:50","pubTimestamp":1742215800,"startTime":"0","endTime":"0","summary":"- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy. - Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment. - Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy. Actimab-A + CLAG-M produced high rates of measurable residual disease negativity  including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy. Dr. Sameem Abedin, Associate Professor of Medicine at the Medical College of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4192","BK4539","CR","NCI","OS","BK4139","ATNM","MCW","BK4535","BK4161","HMA","BK4202","BK4097"],"gpt_icon":0},{"id":"2519809876","title":"ORYZON to Provide Corporate Progress Updates at Several Events in March-April","url":"https://stock-news.laohu8.com/highlight/detail?id=2519809876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519809876?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:00","pubTimestamp":1741953600,"startTime":"0","endTime":"0","summary":"MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS  and iadademstat in oncology . The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-corporate-progress-updates-several-120000379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU1162221912.USD","LU0106261372.USD","LU1363072403.SGD","BK4581","BK4139","LU1989772840.SGD","BK4554","BK4585","BK4588","LU2286300806.USD","LU1732799900.SGD","LU0267386448.USD","LU2111349929.HKD","LU2133065610.SGD","LU1074936037.SGD","LU2347655156.SGD","IE00BZ1G4Q59.USD","BK4534","LU0971096721.USD","BK4116","LU0006306889.USD","LU1720051017.SGD","BK4548","LU0158827948.USD","LU1989772923.USD","LU2023251221.USD","BK4202","IE00BKVL7J92.USD","LU2089284900.SGD","NET","LU0106831901.USD","LU0314104364.USD","PRGS","BK4127","BK4516","NCI","ORYZF","LU0912757837.SGD","LU0225283273.USD","LU0320765646.SGD","LU0795875169.SGD","LU1548497426.USD","LU2357305700.SGD","LU2028103732.USD","BK4613","LU0158827781.USD","LU0098860793.USD","LU0795875086.SGD","LU1732800096.USD"],"gpt_icon":0},{"id":"2518070831","title":"Tempus Announces Acquisition of Deep 6 AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070831","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518070831?lang=en_us&edition=fundamental","pubTime":"2025-03-12 05:15","pubTimestamp":1741727700,"startTime":"0","endTime":"0","summary":"Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network. CHICAGO, March 11, 2025----Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence  with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record  data across a broad ecosystem, which includes academic medical centers, National Cancer Institute -Designated Cancer Centers, and NCI Community Oncology Research Programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-announces-acquisition-deep-6-211500475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4096","SG9999011175.SGD","BK4597","BK4588","LU1861559042.SGD","NCI","SG9999003800.SGD","IE00BVYPNW00.USD","IE00BDGV0183.EUR","EMR","LU2355687059.USD","IE00B42XCP33.USD","BK4585","IE00BVYPNV92.GBP","IE00B3PB1722.GBP","BK4611","BK4543","TEM","BK4121","BK4533","BK4613","BK4202","IE00BGHQF631.EUR","LU1861558580.USD"],"gpt_icon":1},{"id":"2518745220","title":"Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745220","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745220?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:30","pubTimestamp":1741696200,"startTime":"0","endTime":"0","summary":"Represents first ever triplet combination using targeted radiotherapy as a backbone therapy inAML with initial clinical data expected in 2H:2025. Dr. Avinash Desai, Actinium's Chief Medical Officer, commented, \"We are incredibly excited that the first Actimab-A trial initiated under our CRADA with the NCI is this triplet combination with Venetoclax and Taiho's ASTX-727. While Ven-HMA has positively impacted outcomes in AML, a significant number of patients have poor responses or relapse quickly resulting in dismal outcomes. We believe Actimab-A's potentially synergistic, and mutation agnostic mechanism of action can improve clinical outcomes for these patients by producing deeper remissions, including measurable residual disease negativity, that are more durable. Due to its mutation agnostic mechanism, Actimab-A can overcome high-risk features, such as TP53 mutations, and has demonstrated the ability to improve outcomes in these patients where Ven-HMA has had limited success. This trip","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-initiation-actimab-123000179.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-initiation-actimab-123000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","NCI","HMA","BK4139","ATNM","BK4161","BK4202"],"gpt_icon":0},{"id":"2518008200","title":"Nine's Domain tax bill could reach $240 million if CoStar agrees deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2518008200","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518008200?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:00","pubTimestamp":1741636826,"startTime":"0","endTime":"0","summary":"Media giant Nine Entertainment  faces a potential capital gains tax bill of around $240 million if property portal Domain  agrees to a $4.20 per share takeover bid by US investor CoStar, according to market sources.Nine owns 60 per cent of Domain and the tax bill on any share sale means the after-tax value of CoStar's offer to the media group's shareholders may be as little as $3.57 per share.On Monday, Domain shares changed hands for $4.41 at an unusual 5% premium to the takeover bid price, as traders and hedge funds bet on CoStar lifting its offer as it faces push back from Domain's board partly on tax issues.Sources added this deal is far less likely to fall over on a tax shock than Kohlberg Kravis Roberts'bid for part of Perpetual , where the asset manager believed it had structured the deal to minimise tax before the Australian Tax Office took a different view.The difference - or estimated capital gain - of $797.6 million equals a bill of $239.3 million when applying a 30% tax rat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/nine-s-domain-tax-bill-could-reach-240-million-if-costar-agrees-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/nine-s-domain-tax-bill-could-reach-240-million-if-costar-agrees-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4548","LU2095319765.USD","BK4588","LU0708995401.HKD","NEC.AU","LU0672654240.SGD","LU0390134368.USD","BK4123","DHG.AU","IE0009356076.USD","BK7002","IE0004445239.USD","BK4202","BK7062","BK4079","LU0320765059.SGD","NCI","LU0109391861.USD","BK4585","LU1267930730.SGD","LU2210149790.SGD","BK7503","CSGP","PPT.AU","MRN.AU","BK7052","LU2210150020.SGD"],"gpt_icon":0},{"id":"2518415293","title":"Shell plc Fourth Quarter 2024 Euro and GBP Equivalent Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518415293","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518415293?lang=en_us&edition=fundamental","pubTime":"2025-03-10 15:00","pubTimestamp":1741590000,"startTime":"0","endTime":"0","summary":"SHELL PLC FOURTH QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS. The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the fourth quarter 2024 interim dividend, which was announced on January 30, 2025 at US$0.358 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by February 28, 2025 will be entitled to a dividend of US$0.358, 0.3315 or 27.79p per ordinary share, respectively.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling, at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-fourth-quarter-2024-070000764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2236285917.USD","LU0300736062.USD","BK4201","BK4202","LU1162221912.USD","LU0098860793.USD","BK4585","NCI","BK4588","LU0278409577.USD","LU0320765646.SGD","SHEL","LU0300736492.USD"],"gpt_icon":0},{"id":"2517482850","title":"Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482850?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","CNS","BK4097","BK4135","NCI","OS","BK4202"],"gpt_icon":0},{"id":"2517694151","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517694151","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517694151?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"HOUSTON, March  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4202","BK4183","NCI","CSF","LENZ","ODD"],"gpt_icon":0},{"id":"2516648793","title":"Shell plc announces changes to the Executive Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2516648793","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516648793?lang=en_us&edition=fundamental","pubTime":"2025-03-04 15:00","pubTimestamp":1741071600,"startTime":"0","endTime":"0","summary":"London, March 4, 2025  In line with its ongoing transformation, Shell announces further changes to its Executive Committee and leadership structure to support its strategy to deliver more value with less emissions.After more than a decade of distinguished service with Shell, Integrated Gas and Upstream Director, Zo Yujnovich, will step down effective 31 March 2025. Zo will assist with the transition, after which she will leave the Group. Cederic Cremers is appointed President, Integrated Gas, and Peter Costello is appointed President, Upstream, with both joining the Executive Committee effective 1 April 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-announces-changes-executive-070000125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0300736062.USD","BK4201","LU1162221912.USD","BK4585","LU0098860793.USD","BK4202","LU0300736492.USD","LU0320765646.SGD","LU2236285917.USD","SHEL","LU0278409577.USD","BK4588","NCI"],"gpt_icon":1},{"id":"2516635992","title":"Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635992","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635992?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat  to other anti-CDI antibiotics in a germ-free mouse model. Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin -or metronidazole -treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity. Notable differences were observed between the microbiome of IBZ- and fidaxomicin -treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies. Results establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX. Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI. IBZ has previously been granted FDA QIDP a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-announces-publication-nonclinical-vivo-130000861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","LU1571399168.USD","LU0310800965.SGD","ACXP","BK4194","BK4539","BK4563","BK4139","LU0128525689.USD","NCI","BK4202","ECC","VRE","BK4162","LU1496350502.SGD","LU1267930227.SGD","BK4131","BK4181","LU1291159041.SGD","BK4215","MET","FDX","LU1989772923.USD","LU1989772840.SGD","MAA","BK4585","LU0251142724.SGD","IDSA","GAIN","BK4135","LU0048573561.USD","LU1989771016.USD","PK","LU0052756011.USD","BK4588","LU0251131958.USD","BK4533","LU0742534661.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-05-02","current":4.29948,"percent":0.062762,"low":-615.963293,"twenty":6.295892,"median":15.579323,"eighty":24.363962,"high":50.080918,"avg":6.848055,"sd":52.151644,"marketCap":6100064},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000},{"date":"2025-04-25","current":5.587097,"twenty":6.410478,"median":15.712059,"eighty":24.4461,"marketCap":7924800},{"date":"2025-05-02","current":4.29948,"twenty":6.295892,"median":15.579323,"eighty":24.363962,"marketCap":6100064}],"updateTime":1746269951146}}}